Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857676 | 0.86 | ERN1 (0.54) | ERN1PIM1MCL1 | |
| SCHEMBL22897459 | 0.84 | ERN1 (0.52) | ERN1PIM1MCL1 | |
| SCHEMBL22897458 | 0.81 | ERN1 (0.57) | ERN1PIM1 | |
| SCHEMBL10962826 | 0.81 | ERN1 (0.63) | ERN1MEN1LMNAHTTKMT2A | |
| SCHEMBL29425550 | 0.81 | ERN1 (0.57) | ERN1PIM1 | |
| SCHEMBL27945834 | 0.78 | ERN1 (0.46) | ERN1MEN1KMT2A | |
| SCHEMBL23268461 | 0.76 | ERN1 (0.52) | ERN1PIM1 | |
| SCHEMBL16648398 | 0.76 | ERN1 (0.47) | ERN1 | |
| SCHEMBL26874970 | 0.74 | MCL1 (0.53) | ERN1LMNAMCL1 | |
| SCHEMBL15789359 | 0.74 | ERN1 (0.65) | ERN1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355833-A1 | RADIOPAQUE POLYMERS | BIOCOMPATIBLES UK LIMITED (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230279172-A1 | RADIOPAQUE POLYMERS | Boston Scientific Medical Device Limited (IE) | 2023-09-07 | — | — | US | disclosed |
| WO-2021009734-A1 | RADIOPAQUE POLYMERS | BIOCOMPATIBLES UK LIMITED (GB) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279172-A1 | RADIOPAQUE POLYMERS | SSTR3, VHL, PLG | ERN1 2648/4885MEN1 55/4885LMNA 2329/4885 |
| US-20230355833-A1 | RADIOPAQUE POLYMERS | TPO, PGLS, IQGAP1 | ERN1 3496/4885MEN1 246/4885LMNA 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.